StockNews.AI
KALV
StockNews.AI
21 days

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

1. KALV receives FDA approval for EKTERLY, a treatment for HAE. 2. The approval marks a significant growth opportunity for KALV.

Earnings
-8.88%Current Return
VS
+0.9%S&P 500
$15.3909/11 07:14 AM EDTEvent Start
$14.023809/12 01:45 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA approval of EKTERLY establishes KALV as a leader in HAE treatments, similar to past successes of other biotech stocks that surged post-FDA approvals.

How important is it?

The FDA approval is a pivotal moment for KALV's strategic growth, indicating a strong potential for increased revenue and market presence.

Why Long Term?

Successful launch and market traction of EKTERLY will provide sustained revenue growth over time, akin to historical trends observed with newly approved therapies.

Related Companies

PTGXTHLDNBIX
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. “This quarter marked a defining moment in the history of KalVista with the FDA approval of EKTERLY—the first and only oral on-demand treatment for HAE,” stated Ben Palleiko, CEO of KalVista. “Approval and launch on the same day propelled us immediately into our next chapter of growt.

Related News